How to read this page
Retatrutide is investigational, so there is no product label listing its side effects. What exists is trial data: a phase 2 obesity trial (Jastreboff et al., NEJM 2023; 338 participants, 48 weeks), a phase 2 type 2 diabetes trial (Rosenstock et al., Lancet 2023), a phase 1 programme, and the first full phase 3 report, TRANSCEND-T2D-1 (Bajaj et al., Lancet, June 2026; 537 participants, 40 weeks). Everything below comes from those publications. Trial populations are selected and monitored, so the rates seen there are a floor, not a ceiling, for what broader use would show.
Gastrointestinal effects: the most common, and dose-related
As with every GLP-1-based drug, nausea, diarrhoea, vomiting and constipation were the most frequent adverse events. In the phase 2 obesity trial they were dose-related, mostly mild to moderate, clustered during dose escalation, and — importantly — partially mitigated by starting at 2 mg rather than 4 mg before escalating. The phase 3 diabetes trial described the same pattern and added that the events subsided over time. GIP receptor activity is thought to soften GLP-1-related nausea somewhat, which is one argument for the dual and triple agonists, but the effect is not eliminated.
Heart rate: the glucagon signal
The phase 2 obesity trial reported dose-dependent increases in heart rate that peaked at around 24 weeks and declined thereafter. Approved GLP-1 agonists raise resting heart rate by a few beats per minute; glucagon receptor agonism appears to add to that, at least transiently. Whether this has any clinical consequence is precisely what the TRIUMPH-Outcomes cardiovascular trial exists to answer, and it had not reported as of September 2026. Until it does, heart-rate effects are a monitored signal, not a resolved question.
Skin sensitivity (dysesthesia)
The phase 2 programme reported dysesthesia — altered or heightened skin sensation, sometimes described as tingling or sensitivity to touch — more often with retatrutide than placebo, particularly at higher doses. This is not a typical GLP-1 agonist effect and its mechanism has not been established; it has been noted with other glucagon-receptor-active compounds. It was generally mild and did not drive most discontinuations, but it is one of the two features that distinguish retatrutide's profile from tirzepatide's.
Discontinuations and serious events
In TRANSCEND-T2D-1, discontinuation of study drug because of adverse events was 2–5% across the retatrutide arms versus 0% with placebo; no severe hypoglycaemia was reported; and two deaths occurred, both in the 4 mg group and both judged unrelated to the drug. In the phase 2 obesity trial, discontinuation was more common at higher doses and with the faster escalation schedule. These rates are in the range seen with tirzepatide in SURMOUNT-1 (4–7% depending on dose) and semaglutide in STEP 1 (about 7%).
| Finding | Source | Detail |
|---|---|---|
| GI events most common, dose-related | Phase 2 obesity (NEJM 2023) | Mostly mild–moderate; lower 2 mg start reduced them |
| Heart rate increase | Phase 2 obesity (NEJM 2023) | Dose-dependent; peaked ~24 wk, then declined |
| Dysesthesia | Phase 2 programme | More frequent than placebo at higher doses |
| AE discontinuation | TRANSCEND-T2D-1 (Lancet 2026) | 2–5% retatrutide vs 0% placebo |
| Severe hypoglycaemia | TRANSCEND-T2D-1 (Lancet 2026) | None reported |
Class warnings that apply to every incretin
Approved GLP-1 and GIP/GLP-1 agonists carry a consistent set of label warnings, and there is no reason to expect a triple agonist to escape them: a boxed warning about thyroid C-cell tumours seen in rodents (contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2); acute pancreatitis; gallbladder disease; hypoglycaemia when combined with insulin or sulfonylureas; acute kidney injury secondary to dehydration from vomiting or diarrhoea; severe gastrointestinal disease including gastroparesis; and, more recently, pulmonary aspiration under anaesthesia because of delayed gastric emptying. Retatrutide's trials excluded people at highest risk for several of these, so trial data cannot rule them out.
What glucagon agonism adds — both directions
The glucagon receptor is what makes retatrutide different, and it cuts both ways. On the benefit side, glucagon agonism drives fat oxidation in the liver: the phase 2 MASLD substudy reported large reductions in liver fat, with most participants at higher doses reaching normal liver-fat levels. On the caution side, glucagon raises glucose and heart rate, and the molecule's receptor balance was tuned to keep the incretin effects dominant. The phase 2 and phase 3 diabetes trials showed HbA1c falling by up to about 2 percentage points, so the glucose concern did not materialise at the doses studied; the heart-rate effect did.
Hair loss, fatigue and other questions people ask
Hair loss is not reported as a distinct signal in the published retatrutide abstracts, but the labels of approved GLP-1 products list it in a small percentage of users (about 5% with tirzepatide, 3% with semaglutide, versus around 1% on placebo), and it is generally attributed to rapid weight loss rather than the drug itself. Fatigue is common early in treatment across the class and is usually linked to reduced intake. Muscle loss accompanies any large weight reduction; retatrutide's body-composition substudy reported that lean mass fell alongside fat mass, as with other agents. None of these has retatrutide-specific data yet.
Is retatrutide safe? What can and cannot be said
In trials totalling a few thousand participants over up to 48 weeks, retatrutide's adverse-event profile resembled the approved incretins, with heart-rate and dysesthesia signals added. That is the honest summary. What cannot yet be said is anything about cardiovascular outcomes, long-term safety, effects in people excluded from trials, or interactions — the questions phase 3 and post-marketing surveillance exist to answer. For anything sold online as retatrutide, none of the trial data applies at all: vial contents, dose accuracy, sterility and endotoxin levels are unverified, and independent testing of such products has repeatedly found problems. This page is educational and is not medical advice.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Jastreboff et al. (2023) — Retatrutide for obesity, phase 2 trial
Phase 2 obesity trial: studied regimens, weight and adverse events. Trial doses are not instructions for personal use.
Relevant sections: How to read this page · Gastrointestinal effects: the most common, and dose-related · Heart rate: the glucagon signal · Discontinuations and serious events · Is retatrutide safe? What can and cannot be said
- Bajaj et al. (2026) — TRANSCEND-T2D-1, retatrutide phase 3 trial
Published phase 3 diabetes trial; not all phase 3 programs and not a regulatory authorization.
Relevant sections: Skin sensitivity (dysesthesia) · Discontinuations and serious events
- Rosenstock et al. (2023) — Retatrutide in type 2 diabetes, phase 2 trial
Phase 2 diabetes trial; its glycemic endpoints, participants and regimens differ from the obesity study.
Relevant sections: Gastrointestinal effects: the most common, and dose-related · Discontinuations and serious events
FAQ
What are the most common side effects of retatrutide?+
Nausea, diarrhoea, vomiting and constipation — dose-related, mostly mild to moderate, and reduced by starting at a lower dose. A dose-dependent rise in heart rate and skin sensitivity (dysesthesia) were also reported.
Is retatrutide safe?+
In trials so far its profile resembled approved GLP-1 and GIP/GLP-1 drugs, with heart-rate and dysesthesia signals added. Long-term and cardiovascular safety are still being studied; it is not approved anywhere as of September 2026.
Does retatrutide cause hair loss?+
It has not been reported as a distinct signal in the published trials. Approved GLP-1 products list hair loss in roughly 3–5% of users, generally attributed to rapid weight loss.
Does retatrutide raise heart rate?+
Yes. The phase 2 obesity trial reported a dose-dependent increase that peaked around 24 weeks and declined afterward. The cardiovascular outcomes trial has not yet reported.
Does retatrutide make you tired?+
Fatigue is common early in treatment across the incretin class and is usually linked to reduced food intake. No retatrutide-specific fatigue data have been published.
How were side effects reduced in the trials?+
By starting at 2 mg rather than 4 mg and escalating gradually. The phase 2 obesity trial found the lower start partially mitigated gastrointestinal events.